| Document |
Document Title |
|
WO/2022/191278A1 |
A compound which is represented by formula (1). (In formula (1), A represents a substituted or unsubstituted aromatic hydrocarbon ring group which has a fused ring composed of 5 or more rings, while containing a nitrogen atom as a part o...
|
|
WO/2021/174176A9 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2022/188709A1 |
The present invention relates to a thiophene compound and an application thereof. The present invention specifically relates to a compound represented by formula (II) and a pharmaceutically acceptable salt thereof, wherein L1 is -C(=O)- ...
|
|
WO/2022/191570A1 |
The present invention relates to a high-efficiency organic light-emitting device having excellent light-emitting characteristics in light-emitting efficiency, etc. by employing an anthracene derivative compound having a characteristic st...
|
|
WO/2022/192745A1 |
Disclosed are compounds of Formula IIA, IIA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in metho...
|
|
WO/2022/191569A1 |
The present invention provides a novel compound and an organic light emitting device comprising same.
|
|
WO/2022/186133A1 |
In agricultural and horticultural crop production, there is still a great amount of damage due to pests and the like. Thus, the present invention addresses the problem of providing a novel agricultural/horticultural pesticide from the vi...
|
|
WO/2022/182547A1 |
This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.
|
|
WO/2022/179528A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formula (A), (A*), (I), (IIA), or (IIB). Further described herein are pharmaceut...
|
|
WO/2022/179524A1 |
A tricyclic compound as represented by formula (I), a preparation method therefor, and an application thereof as an HIF2α inhibitor.
|
|
WO/2022/181157A1 |
Provided are a compound that improves the performance of an organic EL element, an organic electroluminescent element having improved element performance, and an electronic device including such an organic electroluminescent element, the...
|
|
WO/2022/181933A1 |
The present specification relates to a heterocyclic compound, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/182134A1 |
The present specification relates to a compound and an organic light-emitting device comprising same.
|
|
WO/2022/181508A1 |
The present invention provides: a compound which improves the performance of an organic EL element; an organic electroluminescent element which has improved element performance; and an electronic device which comprises such an organic el...
|
|
WO/2022/179529A1 |
Provided are TNIK and/or MAP4K4 kinases inhibitors for the treatment of disease. In one aspect, disclosed herein are kinase inhibitors having a structure of Formulas (A), (A*), (I), (II), (AA), (B), (C), (D), (B*), (C*) and (D*). Further...
|
|
WO/2022/182623A1 |
Polyfluorinated compounds are disclosed, including polyfluorinated cannabinoid and cannabinoid-like compounds. Also disclosed are methods of producing the polyfluorinated compounds.
|
|
WO/2022/180136A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2022/177401A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2022/177399A1 |
The present invention provides a novel compound, and an organic light emitting device comprising same.
|
|
WO/2022/177398A1 |
The present invention relates to a novel compound and an organic light-emitting device comprising same. A compound represented by chemical formula 1 may be used as a material for an organic material in an organic light-emitting device, a...
|
|
WO/2022/177404A1 |
The present invention provides a novel compound, and an organic light-emitting device using same.
|
|
WO/2022/178030A1 |
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential melastatin 8 receptor (TRPM8) activity.
|
|
WO/2022/176017A1 |
The present invention provides: an amorphous solid dispersion which contains a compound (I); an amorphous material (amorphous substance) which contains the compound (I) and an organic acid; an amorphous solid dispersion which contains th...
|
|
WO/2022/176877A1 |
An amorphous solid dispersion containing compound (I); an amorphous form comprising compound (I) and an organic acid; an amorphous solid dispersion containing the amorphous form; a medicinal composition containing the amorphous form or a...
|
|
WO/2022/172296A1 |
The present invention relates to a process for preparation of Navafenterol of Formula (I) and intermediate compounds of Formula (VII) and Formula (XIII) by chiral sulfide mediated epoxidation. The process involves preparation of the inte...
|
|
WO/2022/173805A1 |
The present application discloses novel compounds, pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a compound of the d...
|
|
WO/2022/170737A1 |
A thienopyrimidine compound (a compound of formula N) and a preparation method therefor. Specifically, the provided preparation method comprises the steps of: (a) in a solvent A, reacting, in the presence of an organic base and acyl chlo...
|
|
WO/2022/173849A1 |
The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt, or a stereoisomer and their use in, e.g. treating a condition, disease or disorder modulated at least in part by CCR6. This disclosure also fea...
|
|
WO/2022/173022A1 |
The purpose of the present invention is to, in order to improve the light extraction efficiency of an organic EL element, provide a compound that has a low extinction coefficient and a high refractive index in a range of 450-750 nm in a ...
|
|
WO/2022/171653A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2022/168761A1 |
A compound represented by formula (1) or (2) (wherein the symbols are as defined in the specification); an organic electroluminescent element including the compound; and an electronic appliance including such organic electroluminescent e...
|
|
WO/2022/170122A1 |
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, ...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/167819A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof Formula (I) wherein R2, R3, R4, X1, X2, X3 and X4 are as defined in the specification, processes for t...
|
|
WO/2022/169997A1 |
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/167682A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/160637A1 |
A 3-aryl-6-aralkyl-1,4,5,6-tetrahydropyridazine compound, having the structure as shown in formula I. γ, δ-unsaturated N-aryl sulfonyl substituted hydrazone is subjected to a cyclization rearrangement reaction by means of a light and r...
|
|
WO/2022/161274A1 |
Disclosed in the present invention are a pyrimidine-2,4-diamine compound, a preparation method therefor and the use thereof, relating to the technical field of pharmaceutical chemistry. The pyrimidine-2,4-diamine compound of the present ...
|
|
WO/2022/161496A1 |
The present disclosure provides compounds having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein variables are as defined as set forth in the specification. The present disclosure also provides compound...
|
|
WO/2022/161166A1 |
A targeting chimeric compound, a pharmaceutical composition comprising same, a preparation method therefor and use thereof. The targeting chimeric compound is as represented by general formula (I), and each substituent in the general for...
|
|
WO/2022/163735A1 |
The present invention provides a compound that improves the performance of an organic EL element, an organic electroluminescent element having improved element performance, and an electronic device including such an organic electrolumine...
|
|
WO/2022/157499A1 |
The invention relates to protected HDAC inhibitor compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are as defined herein. In aspects, the inventions relates to use of the compounds, and to methods of deprotecting the compounds.
|
|
WO/2022/155981A1 |
Disclosed is the use of an N-heterocyclic carbene-based compounded nickel (II) complex in the synthesis of an α-benzyl benzofuran compound. In the present invention, an air-stable compounded nickel (II) complex Ni[P(OEt)3]{[R`NC(CH3)C(C...
|
|
WO/2022/152097A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2022/154282A1 |
The present specification relates to: a compound of chemical formula 1; and an organic light-emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first electrode and the se...
|
|
WO/2022/154283A1 |
The present specification relates to a compound and an organic light-emitting device comprising same.
|
|
WO/2022/153962A1 |
The problem to be solved by the present invention is to provide: a compound useful as a hole transport material for photoelectric conversion elements whereby electric current can be efficiently taken out; and a photoelectric conversion e...
|
|
WO/2022/147620A1 |
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs...
|
